Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Durect: Q2 Earnings Snapshot

07/29/2021 | 06:19pm EDT

CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Thursday reported a second-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.

On a per-share basis, the Cupertino, California-based company said it had a loss of 4 cents.

The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 4 cents per share.

The specialty pharmaceutical company posted revenue of $2.3 million in the period, which did not meet Street forecasts. Three analysts surveyed by Zacks expected $2.8 million.

In the final minutes of trading on Thursday, the company's shares hit $1.51. A year ago, they were trading at $1.97.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DRRX at https://www.zacks.com/ap/DRRX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about DURECT CORPORATION
09/15DURECT CORPORATION : Fireside Chat at Oppenheimer's Fall Healthcare Life Science..
PR
09/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright Annual Global Investme..
PR
08/02DURECT : Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target
MT
08/02DURECT : Files for Up to $250 Million Mixed-Securities Shelf
MT
07/30DURECT : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
07/29DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q2 Revenue $2.3M, vs. ..
MT
07/29DURECT CORPORATION : Announces Second Quarter 2021 Financial Results and Update ..
PR
More news
Analyst Recommendations on DURECT CORPORATION
More recommendations
Financials (USD)
Sales 2021 8,56 M - -
Net income 2021 -40,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,15x
Yield 2021 -
Capitalization 298 M 298 M -
Capi. / Sales 2021 34,8x
Capi. / Sales 2022 20,1x
Nbr of Employees 79
Free-Float 98,6%
Chart DURECT CORPORATION
Duration : Period :
DURECT Corporation Technical Analysis Chart | DRRX | US2666051048 | MarketScreener
Technical analysis trends DURECT CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,31 $
Average target price 6,50 $
Spread / Average Target 396%
EPS Revisions
Managers and Directors
James E. Brown President, Chief Executive Officer & Director
Michael H. Arenberg Chief Financial Officer & Secretary
David R. Hoffmann Chairman
Wei Qi Lin Executive Vice President-Research & Development
David J. Ellis Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
DURECT CORPORATION-36.72%280
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539